Saxenda vs Compounded Liraglutide 3 mg: What Women Need to Know Before Choosing

What Saxenda Is and Why Women Are Prescribed It

Saxenda is a once-daily subcutaneous injection of liraglutide at 3 mg, approved by the FDA in December 2014 for chronic weight management in adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity. The 3 mg dose is distinct from Victoza (liraglutide 1.2 mg and 1.8 mg), which carries a separate approval for type 2 diabetes.

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It reduces appetite and slows gastric emptying by mimicking the action of endogenous GLP-1, a hormone released from the gut after eating. Women respond to appetite and satiety hormones differently from men across the menstrual cycle, and estrogen itself upregulates GLP-1 receptor expression, which is one reason GLP-1 drugs behave differently depending on your hormonal status.

Why Women Seek It Specifically

Weight gain in women is rarely linear. Reproductive events, including puberty, pregnancy, postpartum, and perimenopause, each shift fat distribution and metabolic rate. Women with PCOS carry excess visceral and subcutaneous adiposity driven in part by hyperinsulinemia. Women in perimenopause see a shift from gynoid to central fat accumulation as estrogen falls. These are not simply "weight" problems. They are metabolic and hormonal problems, and liraglutide addresses several of the underlying mechanisms.

The Clinical Evidence: What Was Actually Studied

The foundational trial for Saxenda is the SCALE Obesity and Prediabetes trial, published in the New England Journal of Medicine in 2015. This randomized, double-blind, placebo-controlled study enrolled 3,731 adults with obesity or overweight plus comorbidities. Participants received liraglutide 3 mg or placebo as an adjunct to a reduced-calorie diet and increased physical activity for 56 weeks.

Mean weight loss was 8.0% with liraglutide versus 2.6% with placebo. Approximately 63% of participants on liraglutide lost at least 5% of body weight, compared with 27% on placebo.

What the SCALE Trial Did Not Tell Us

The SCALE trial enrolled roughly 78% women, which is a higher female representation than most cardiovascular trials. That is genuinely good. But the trial did not stratify outcomes by menopausal status, PCOS diagnosis, phase of menstrual cycle at baseline, or concurrent hormonal contraceptive use. Those are real gaps. Subgroup analyses by reproductive status were not pre-specified, so we are extrapolating when we apply the average 8% weight loss figure to a woman in perimenopause on estrogen therapy, or to a woman with PCOS on metformin.

The WomanRx clinical framework for GLP-1 prescribing stratifies expected response by hormonal status because the available trial data does not do this for you. Women in late perimenopause or early postmenopause appear, from smaller observational studies, to respond comparably to premenopausal women in terms of weight loss percentage, but may notice more pronounced GI side effects if they are also on oral estrogen (which delays gastric emptying via a separate mechanism).

SCALE Diabetes and SCALE Maintenance

Two additional SCALE sub-trials are relevant for women. SCALE Diabetes tested liraglutide 3 mg in adults with type 2 diabetes and found a mean weight loss of 6.0% versus 2.0% with placebo at 56 weeks. SCALE Maintenance enrolled adults who had already lost at least 5% of body weight during a low-calorie diet run-in, then randomized them to liraglutide or placebo to assess maintenance. At 56 weeks, liraglutide-treated participants lost an additional 6.2% from randomization versus a 0.2% gain in the placebo group. This maintenance data matters for women who have lost weight through diet alone and want pharmacological support to hold that loss through a hormonally volatile period like perimenopause.

Compounded Liraglutide: What It Is and What It Is Not

Compounded liraglutide is liraglutide prepared by a compounding pharmacy, typically 503A (patient-specific) or 503B (outsourcing facility) pharmacies in the United States. It is not FDA-approved. The FDA has never reviewed the manufacturing process, sterility testing, or bioequivalence of any compounded liraglutide product.

Why Compounding Became Widespread

Starting in 2022 and accelerating through 2023 and 2024, semaglutide (Ozempic, Wegovy) shortages drove enormous demand for compounded GLP-1 products. Compounded liraglutide entered the market as a lower-cost alternative. Because Saxenda itself was not on the FDA drug shortage list for most of this period (unlike semaglutide), compounded liraglutide occupied a legally gray area. The FDA has stated that compounding of FDA-approved drugs that are not on the shortage list raises significant legal and safety concerns.

Quality Control Gaps That Matter

Compounding pharmacies are regulated by state boards of pharmacy and, for 503B facilities, by the FDA. But individual batches of compounded liraglutide are not subject to the same pre-market testing that Saxenda undergoes. Specific risks include:

• Incorrect concentration (overdose or underdose)
• Microbial contamination from non-sterile compounding environments
• Degradation products from improper storage or formulation
• Unlabeled additives (some compounded versions have contained vitamin B12 or other compounds not studied in combination with liraglutide)

The FDA issued a warning in 2024 specifically noting reports of adverse events, including medication errors tied to unit confusion, with compounded GLP-1 receptor agonist products. That warning was primarily about semaglutide, but the mechanism of risk applies equally to compounded liraglutide.

Cost Comparison

Branded Saxenda costs approximately $1,300 to $1,500 per month at retail pharmacy prices without insurance. Compounded liraglutide is typically priced at $200 to $400 per month through telehealth platforms. That price gap is real and matters for access. Women bear a disproportionate share of out-of-pocket healthcare costs. Insurance coverage for Saxenda is inconsistent; many plans exclude weight-loss drugs entirely, and Medicaid coverage varies by state. The cost difference is a legitimate reason women choose compounded versions, and any honest conversation about this topic has to acknowledge that.

Sex-Specific Pharmacology: How Liraglutide Behaves Differently in Women

Women have lower average lean body mass, higher average body fat percentage, different gastric emptying rates at baseline, and different GLP-1 receptor density than men. These are not trivial differences.

Gastric Emptying and GI Side Effects

Liraglutide slows gastric emptying. Women already have somewhat slower gastric transit than men at baseline, a difference that is further modulated by progesterone (which slows gastric motility) and estrogen (which has mixed effects depending on receptor subtype). Research published in Neurogastroenterology and Motility has documented sex differences in gastric emptying that are clinically meaningful. The practical result: women on liraglutide may experience more pronounced nausea, particularly in the luteal phase of the menstrual cycle when progesterone peaks, and during the first 8 to 12 weeks of dose escalation.

Menstrual Cycle Effects

Liraglutide does not directly suppress ovulation at the 3 mg dose in the way that severe caloric restriction can. Women who lose more than 5% of body weight on any intervention, including GLP-1 drugs, sometimes experience changes in cycle length or flow as their hormonal milieu shifts. This is not a pharmacological effect of liraglutide itself but a consequence of fat loss and insulin sensitization. For women with PCOS, this shift is often welcome: improved insulin sensitivity reduces androgen production and can restore more regular cycles.

Drug Interactions with Hormonal Contraception

Liraglutide's effect on gastric emptying could theoretically reduce peak serum concentrations of oral contraceptive pills, particularly ethinyl estradiol and levonorgestrel. A pharmacokinetic study found that liraglutide (at the 1.8 mg Victoza dose) delayed the time to peak concentration of ethinyl estradiol by 1.5 hours and reduced Cmax by approximately 12%, without meaningfully affecting overall exposure (AUC). The clinical significance is likely low for most women, but it is a real interaction that your prescriber should know about, particularly if you are relying on oral contraception for pregnancy prevention while taking a drug that is contraindicated in pregnancy (see below).

Saxenda in PCOS: A Closer Look

PCOS affects approximately 8 to 13% of women of reproductive age and is strongly linked to insulin resistance and difficulty losing weight through lifestyle alone. Liraglutide has been studied specifically in PCOS populations.

What the PCOS Trial Data Shows

A randomized controlled trial published in the Journal of Clinical Endocrinology and Metabolism compared liraglutide 1.2 mg, metformin 1000 mg twice daily, a combination of both, and placebo in women with PCOS over 12 weeks. Liraglutide produced the greatest reduction in body weight and BMI. The combination of liraglutide and metformin produced the greatest improvement in menstrual frequency. Free androgen index improved across all active treatment groups.

These trials used the lower Victoza doses, not the 3 mg Saxenda dose, so we are extrapolating somewhat when prescribing 3 mg specifically for PCOS. The higher dose is expected to produce greater weight loss, which in turn should produce greater hormonal benefit, but the 3 mg dose has not been studied in a dedicated PCOS RCT as of early 2025.

Fertility Implications in PCOS

For women with PCOS who are trying to conceive, liraglutide must be stopped before any conception attempt. It is contraindicated in pregnancy (see the pregnancy section below). The clinical strategy in women with PCOS who want to lose weight before conception is to use liraglutide as a bridge, then transition to metformin (which has more pregnancy safety data) or discontinue medication when actively trying to conceive.

Saxenda in Perimenopause and Postmenopause

The perimenopause transition, typically beginning in the mid-40s, brings a shift in fat distribution toward visceral and abdominal depots even without a change in total body weight. This is driven by falling estrogen, rising FSH, and changes in adipokine signaling. Women in this stage often report that the strategies that previously controlled their weight stop working.

GLP-1 receptor agonists act on hypothalamic appetite centers and on peripheral fat tissue in ways that are not estrogen-dependent. That means they can still work after menopause. Observational data and sub-analyses from larger trials suggest that postmenopausal women achieve weight loss with liraglutide that is comparable to premenopausal women, though the absolute benefit in terms of metabolic risk reduction may differ because the baseline cardiovascular risk profile is different.

Interaction with Menopausal Hormone Therapy

Women on oral estrogen-containing menopausal hormone therapy (MHT) should be aware of the same gastric-emptying pharmacokinetic interaction described above for oral contraceptives. Transdermal estrogen bypasses first-pass gut absorption entirely and is not subject to this interaction. The Menopause Society notes that transdermal estradiol carries a lower thrombotic risk than oral formulations, a consideration that is independent of GLP-1 use but worth noting for women managing both obesity and menopausal symptoms.

Bone Health Warning

Postmenopausal women already face accelerated bone loss. The SCALE Obesity and Prediabetes trial found a modestly higher rate of bone fractures in the liraglutide group versus placebo (2.9% vs 1.9%), though this did not reach statistical significance and may have reflected confounding by physical activity. Bone density should be monitored with DEXA in postmenopausal women who are on long-term liraglutide therapy, particularly if they are also not on MHT.

Pregnancy, Lactation, and Contraception Requirements

This section is mandatory for any drug article on WomanRx, and for liraglutide specifically it carries real urgency.

Pregnancy: Contraindicated

Liraglutide is FDA Pregnancy Category C (prior to 2015 labeling changes) and under current labeling is classified as contraindicated based on animal data showing fetal harm. In animal reproduction studies, liraglutide caused embryofetal toxicity, including reduced growth, skeletal abnormalities, and neonatal deaths at doses producing maternal plasma exposures overlapping with human clinical exposures.

There are no adequate and well-controlled studies of liraglutide in pregnant women. The FDA label states clearly: "Saxenda is contraindicated during pregnancy."

If you are planning a pregnancy, stop Saxenda at least 2 months before your planned conception attempt. Liraglutide has a half-life of approximately 13 hours after subcutaneous injection, so it clears relatively quickly compared to semaglutide (half-life approximately 1 week), but the 2-month washout is a conservative and reasonable clinical standard given the animal data.

If you become pregnant while taking Saxenda, stop the medication immediately and contact your obstetric provider.

Contraception Requirement

Because Saxenda is contraindicated in pregnancy, women of reproductive age taking it should use reliable contraception. If you are relying on oral contraceptive pills, the pharmacokinetic interaction described above (12% reduction in Cmax) is worth discussing with your prescriber. Most clinicians would not change this recommendation based on that interaction alone, but adding a barrier method or using a non-oral form of contraception (IUD, implant, injectable, patch, ring) removes the theoretical concern entirely.

Women taking compounded liraglutide should apply the same contraception standards. The contraindication does not change because the formulation is compounded.

Lactation

The FDA label notes that it is unknown whether liraglutide is present in human milk. Liraglutide is a large peptide (molecular weight approximately 3,751 daltons) and is expected to have limited oral bioavailability if transferred to breast milk, because it would be degraded in the infant's gut. However, the absence of human lactation data means we cannot confirm safety for the nursing infant. Current guidance advises against using Saxenda while breastfeeding. Weight loss through GLP-1 drugs during lactation also raises theoretical concerns about caloric adequacy for milk production.

Who Is a Good Candidate vs. Who Should Not Take Saxenda

Women Who May Benefit Most

• Women with PCOS and insulin resistance who have not achieved adequate weight loss with metformin and lifestyle change alone
• Women in perimenopause with new-onset central weight gain despite unchanged diet and activity
• Postmenopausal women with obesity and cardiovascular risk factors, particularly those not using MHT
• Women with prediabetes aiming to prevent progression to type 2 diabetes (the SCALE Prediabetes arm showed a 66% lower rate of progression to diabetes with liraglutide versus placebo at 3 years)
• Women who tried lifestyle modification alone for 6 months or more without reaching a clinically meaningful weight loss target

Women Who Should Not Take Saxenda

• Pregnant women or those actively trying to conceive
• Women who are breastfeeding
• Women with a personal or family history of medullary thyroid carcinoma (liraglutide carries a boxed warning for this risk, based on animal data)
• Women with Multiple Endocrine Neoplasia syndrome type 2
• Women with a history of pancreatitis (use is generally avoided; liraglutide is associated with a small increased risk of acute pancreatitis)
• Women with severe renal impairment or end-stage renal disease (dose adjustment data are limited)

Branded vs. Compounded: A Direct Comparison by Decision Factor

| Decision Factor | Branded Saxenda | Compounded Liraglutide | |---|---|---| | FDA approval | Yes | No | | Bioequivalence verified | Yes | No | | Sterility testing | Batch-released by Novo Nordisk | Varies by pharmacy | | Clinical trial data | SCALE program (5 RCTs) | None specific to compounded product | | Concentration accuracy | Highly consistent | Not externally verified | | Cost (monthly, no insurance) | ~$1,300-$1,500 | ~$200-$400 | | Pregnancy contraindication | Same | Same | | Pharmacist or prescriber oversight | Required | Required (varies by telehealth platform) |

The evidence for efficacy is entirely on the branded side. The cost advantage is entirely on the compounded side. Women making this decision deserve an honest accounting of both.

The FDA's Current Position on Compounded GLP-1 Products

The FDA's stance has evolved as the GLP-1 shortage situation changed. As of early 2025, Saxenda (liraglutide 3 mg) is not on the official FDA drug shortage database, which means the primary legal justification for compounding it under 503A and 503B frameworks is narrower than it was for semaglutide during the Wegovy shortage. The FDA has stated that compounding a drug that is not in shortage, that is a copy of an approved product, raises compliance concerns under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

That regulatory context matters for women using compounded liraglutide through telehealth platforms. The legality of your prescription may depend on your state's compounding pharmacy regulations and on whether your specific pharmacy is operating as a 503A or 503B facility.

What to Ask Your Prescriber Before Starting Either Version

Before starting Saxenda or a compounded liraglutide product, bring these specific questions to your appointment:

1. Is this pharmacy a 503A or 503B facility, and does it have current USP <797> or <800> compliance?
2. What is the exact concentration of liraglutide in this compounded vial, and how do I convert units to doses?
3. Given my current contraceptive method, do I need to add or switch anything?
4. How will we monitor my thyroid, particularly if I have a family history of thyroid disease?
5. If I am on oral estrogen (OCP or MHT), does my prescriber know about the gastric-emptying interaction?
6. At what point would we consider switching to semaglutide (Wegovy) given the stronger cardiovascular outcome data from the SELECT trial?

A clinician who cannot or will not answer these questions directly is not providing an adequate level of care for a prescription-only drug in a contraindicated-in-pregnancy category.